Regeneron Pharmaceuticals, Inc.

Harikiran Nistala

Chia-Jen Siao

Claudia Gonzaga-Jauregui

Cristopher Van Hout

Lyndon Mitnaul

Kalyan C Nannuru

Anthony Marcketta

The present disclosure provides methods of treating subjects having increased serum glucose level and/or hyperglycemia, methods of identifying subjects having an increased risk of developing increased serum glucose level and/or hyperglycemia, and methods of detecting human Solute Carrier Family 39 Member 5 variant nucleic acid molecules and variant polypeptides.

Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

This disclosure relates to a rodent model of Steel Syndrome. Disclosed herein are genetically modified rodent animals that carry a mutation in an endogenous rodent Col27a1 gene, equivalent to a mutation in humans causing Steel Syndrome.

Rodent model of steel syndrome

Growing community of inventors

Tarrytown, NY, United States of America

Harikiran Nistala